Table 2.
Clinical outcomes of patients based on time of granulocyte colony-stimulating factor (GCSF) initiation.
| Outcomes | Day +1 group (N=100) |
Day +5 group (N=100) |
P-value |
|---|---|---|---|
|
Number of GCSF vial infusions, n
Range Median (IQR) Mean ± SD |
7 – 31 14 (11.25 – 22) 14.67 ± 5.25 |
6 – 29 13 (11 – 16) 13.2 ± 5.21 |
0.005 |
|
Time to neutrophil engraftment, days
Range Median (IQR) Mean ± SD |
8 – 22 11 (11 – 12) 12.25 ± 2.8 |
8 – 21 11 (10 – 13) 11.62 ± 2.13 |
0.14 |
|
Time to platelet engraftment, days
Range Median (IQR) Mean ± SD |
6 – 25 14 (12 – 21) 14 ± 3.75 |
9 – 22 12 (11 – 14) 12.69 ± 2.4 |
<0.001 |
|
Duration of fever, days
Range Median (IQR) Mean ± SD |
0 – 12 2 (1 – 3) 2.27 ± 1.88 |
0 – 11 2 (1 – 3) 2.11 ± 1.83 |
0.13 |
|
Duration of hospitalization after transplantation, days
Range Median (IQR) Mean ± SD |
11 – 27 18 (15.25 – 25.75) 18 ± 3.83 |
10 – 22 14 (12.25 – 16) 14.2 ± 2.48 |
<0.001 |
|
The total length of hospitalization, days
Range Median (IQR) Mean ± SD |
20 – 38 29 (26 -35) 29 ± 4.43 |
17 – 40 25 (22 – 28) 25 ± 4.91 |
<0.001 |
| Bacteremia, n (%) | 32 (32.0%) | 27 (27.0%) | 0.46 |
| Fungal infection, n (%) | 6 (6.0%) | 7 (7.0%) | 0.76 |
|
Pretransplantation myelotoxic drug use, n (%) 1
Melphalan Procarbaribe Bendamustine Chlorambucil |
10 (10.0%) 6 (54.5%) 1 (9.1%) 3 (27.3%) 0 (0.0%) |
5 (5.0%) 0 (0.0%) 0 (0.0%) 3 (60.0%) 2 (40.0%) |
0.18 |
| Transfused pack cell units, n (mean) | 1.72 | 0.75 | <0.001 |
| Transfused platelet units, n (mean) | 2.11 | 1.98 | 0.12 |
GCSF, granulocyte colony-stimulating factor; IQR, interquartile range; N, number; SD, standard deviation.
1Histories of myelotoxic drug use prior to transplantation, which may have contributed to delays in mobilization and engraftment.